Laborate Pharmaceuticals India Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Laborate Pharmaceuticals India Limited Pharmaceutical Export Portfolio Dataset — 13 Products, $12.2M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Laborate Pharmaceuticals India Limited — Pharmaceutical Exporter Profile (2026) | 13 Products, $12.2M Trade | TransData Nexus

Laborate Pharmaceuticals India Limited

Indian Pharmaceutical Exporter · Respiratory & OTC Specialist · $12.2M Total Trade · DGFT Verified

Laborate Pharmaceuticals India Limited is an Indian pharmaceutical exporter with a total trade value of $12.2M across 13 products in 7 therapeutic categories. Based on 596 verified export shipments from Indian Customs (DGFT) records, Laborate Pharmaceuticals India Limited is the #1 Indian exporter in 1 product including Streptomycin. Top exports include Caffeine ($3.7M), Vati ($2.2M), Ephedrine ($1.8M).

Laborate Pharmaceuticals India Limited — Export Portfolio & Destination Treemap

Laborate Pharmaceuticals India Limited pharmaceutical export portfolio — 13 products across 7 therapeutic categories. Source: Indian Customs (DGFT).

Who is Laborate Pharmaceuticals India Limited? — Company Overview & Market Position

Laborate Pharmaceuticals India Limited, established in 1985, is a prominent Indian pharmaceutical manufacturer headquartered in Panipat, Haryana. The company is a public unlisted entity, classified as a non-government company limited by shares, with a Corporate Identification Number (CIN) of U24239HR1990PLC030835. Laborate specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to both domestic and international markets.

The company's authorized capital stands at ₹5 crore, with a paid-up capital of ₹4.33 crore, reflecting a paid-up capital percentage of approximately 86.73%. Laborate employs a workforce of over 5,000 individuals, underscoring its significant presence in the pharmaceutical industry. The company's official website is www.laborate.com, providing comprehensive information about its products, services, and corporate initiatives.

What Does Laborate Pharmaceuticals India Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Caffeine$3.7M 2

Product Portfolio — Top 13 by Export Value

Laborate Pharmaceuticals India Limited exports 13 pharmaceutical products across 7 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Caffeine	Respiratory & OTC	$3.7M	87	3.5%	6
2	Vati	Ayurvedic & Herbal Products	$2.2M	270	7.1%	4
3	Ephedrine	Respiratory & OTC	$1.8M	35	7.8%	3
4	Pseudoephedrine	Respiratory & OTC	$1.8M	35	14.7%	2
5	Amikacin	Advanced Antibiotics	$701.0K	62	3.3%	8
6	Chloroquine	Antimalarial & Antiparasitic	$521.3K	42	0.3%	11
7	Sulfadoxine	Antimalarial & Antiparasitic	$400.0K	8	0.7%	6
8	Tetracycline	Antibiotics	$385.4K	17	2.3%	7
9	Bromhexine	Respiratory & OTC	$287.8K	12	1.8%	11
10	Guaifenesin	Respiratory & OTC	$244.6K	7	0.9%	15
11	Streptomycin	Antibiotics	$127.3K	4	22.2%	1
12	Indomethacin	Analgesics & Antipyretics	$61.8K	6	0.7%	14
13	Niacin	Lipid & Metabolism	$31.0K	11	0.8%	9

Laborate Pharmaceuticals India Limited exports 13 pharmaceutical products across 7 therapeutic categories with a total export value of $12.2M. The company is the #1 Indian exporter in 1 product: Streptomycin. The top category is Respiratory & OTC (63.7% of portfolio), followed by Ayurvedic & Herbal Products (18.1%), indicating a concentrated portfolio with the top 5 products accounting for 83.1% of total export value.

Laborate Pharmaceuticals India Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Laborate Pharmaceuticals operates multiple manufacturing units across India, each designed to meet specific production requirements and adhere to international quality standards. The primary manufacturing facility, located in Panipat, Haryana, is WHO-GMP certified and specializes in small volume parenterals, ophthalmic preparations, tablets, capsules, and external preparations.

In 2004, the company expanded its operations with a GMP-certified plant in Paonta Sahib, Himachal Pradesh, equipped with advanced technology for small volume parenterals, ophthalmic preparations, tablets, capsules, dry syrups, and external preparations. The third and largest manufacturing unit, established in 2010 in Paonta Sahib, adheres to USFDA and European GMP standards, producing oral solid dosage forms, injectables, ophthalmic preparations, external applications, oral liquids, and dry syrups.

In 2023, Laborate inaugurated two additional facilities: one in Salwan, Karnal, Haryana, dedicated to the production of Ayurvedic and cosmetic products, and another in Satiwala, Paonta Sahib, Himachal Pradesh, focusing on general products, beta-lactam products, and cephalosporin products.

3Key Leadership

Laborate Pharmaceuticals is led by a team of experienced professionals committed to the company's mission of delivering high-quality, affordable healthcare solutions. The leadership team includes:

Shri Ajay Bhatia: Chairman and Whole-time Director, Shri Bhatia is a first-generation entrepreneur with extensive experience in the pharmaceutical industry. He holds a bachelor's degree in pharmacy and founded Laborate Pharmaceuticals in 1990.

Shri Sanjay Bhatia: Managing Director and co-founder, Shri Bhatia joined Laborate immediately after completing his graduation, contributing significantly to the company's growth and success.

Mr. Parag Bhatia: Director, Mr. Bhatia represents a new generation of pharma leadership, blending international education with strategic foresight. He holds a Master's in International Management from Royal Holloway, University of London, and is driving Laborate's transformative vision to make quality, affordable healthcare accessible globally.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Laborate Pharmaceuticals India Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Laborate Pharmaceuticals has established a robust presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and certifications to market its products in these regions, ensuring compliance with stringent quality and safety standards.

In the United States, Laborate has registered its manufacturing facilities with the FDA and holds approved Abbreviated New Drug Applications (ANDAs) for various products. The company has also filed Drug Master Files (DMFs) for its active pharmaceutical ingredients, facilitating the approval process for its finished dosage forms. Laborate's facilities have undergone FDA inspections, demonstrating adherence to Good Manufacturing Practices (GMP).

In the European Union, Laborate has received EU GMP certificates, allowing it to market its products across member states. The company's commitment to quality is further evidenced by its compliance with the European Directorate for the Quality of Medicines & HealthCare (EDQM) standards.

In the United Kingdom, Laborate's products are authorized for sale, and the company maintains compliance with the Medicines and Healthcare products Regulatory Agency (MHRA) requirements. Similarly, in Australia, Laborate's products are registered with the Therapeutic Goods Administration (TGA), ensuring they meet the country's health and safety standards.

In Japan, Laborate has obtained the necessary approvals to market its products, adhering to the standards set by the Pharmaceuticals and Medical Devices Agency (PMDA).

Emerging Markets

Laborate Pharmaceuticals India Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Laborate Pharmaceuticals has made significant strides in the U.S. market by registering its manufacturing facilities with the FDA. The company holds approved ANDAs for several products, demonstrating its capability to produce generic formulations that meet the FDA's stringent standards.

In addition to ANDAs, Laborate has filed DMFs for its active pharmaceutical ingredients, providing detailed information about the manufacturing process, quality control measures, and stability data. This transparency facilitates the approval of its finished dosage forms and underscores the company's commitment to quality.

Laborate's manufacturing facilities have undergone FDA inspections, confirming compliance with Good Manufacturing Practices (GMP). These inspections assess various aspects of the manufacturing process, including facility conditions, equipment calibration, personnel training, and documentation practices. The successful completion of these inspections reflects Laborate's dedication to maintaining high-quality standards in its operations.

2WHO & EU GMP

Laborate Pharmaceuticals has achieved WHO prequalification for several of its products, affirming their compliance with international quality standards. This certification is essential for supplying medicines to countries participating in the Global Fund and other international health initiatives.

Laborate Pharmaceuticals India Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Laborate Pharmaceuticals operates in a competitive landscape, with several key players in the Indian pharmaceutical industry offering similar product portfolios. Competitors include companies such as Cipla, Sun Pharmaceutical Industries, and Dr. Reddy's Laboratories, which have established global presences and extensive product lines.

In the generic pharmaceutical segment, Laborate faces competition from both domestic and international manufacturers. The company's focus on quality, affordability, and regulatory compliance positions it favorably in the market. However, maintaining a competitive edge requires continuous innovation, efficient manufacturing processes, and strategic partnerships.

Laborate's emphasis on emerging markets provides a unique opportunity to tap into regions with growing healthcare needs. By aligning its product offerings with the specific requirements of these markets, the company can differentiate itself from competitors and establish a strong foothold in underserved areas.

2Key Differentiators

Laborate Pharmaceuticals distinguishes itself through several key differentiators:

Comprehensive Product Portfolio: The company offers a diverse range of over 1,000 products, including generic pharmaceuticals, Ayurvedic medicines, and personal care products, catering to a wide spectrum of healthcare needs.

Frequently Asked Questions — Laborate Pharmaceuticals India Limited

How many pharmaceutical products does Laborate Pharmaceuticals India Limited export from India?

Laborate Pharmaceuticals India Limited exports 13 pharmaceutical products across 7 therapeutic categories. The top exports are Caffeine ($3.7M), Vati ($2.2M), Ephedrine ($1.8M), Pseudoephedrine ($1.8M), Amikacin ($701.0K). Total export value is $12.2M.

What is Laborate Pharmaceuticals India Limited's total pharmaceutical export value?

Laborate Pharmaceuticals India Limited's total pharmaceutical export value is $12.2M, based on 596 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Laborate Pharmaceuticals India Limited the #1 Indian exporter?

Laborate Pharmaceuticals India Limited is the #1 Indian exporter in 1 products: Streptomycin (22.2% market share).

What therapeutic categories does Laborate Pharmaceuticals India Limited cover?

Laborate Pharmaceuticals India Limited exports across 7 therapeutic categories. The largest are Respiratory & OTC (63.7%, 5 products), Ayurvedic & Herbal Products (18.1%, 1 products), Antimalarial & Antiparasitic (7.5%, 2 products).

Get Full Laborate Pharmaceuticals India Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.